The prescription of substitution drugs, such as methadone and buprenorphine, has become a mainstream, first-line treatment for opioid dependence, with around 700 000 of Europe’s 1.3 million problem opioid users receiving substitution treatment today. But a small minority of entrenched opioid users repeatedly fails to respond to interventions of this kind. Findings from international trials now suggest that the supervised use of medicinal heroin can be an effective second-line treatment for this small, and previously unresponsive, group. In this latest EMCDDA Insights report, experts describe the development as ‘an important clinical step forward’. The report provides the first state-of-the-art overview of research on the subject, examining the latest evidence and clinical experience in this area in Europe and beyond.
- Developing a Theoretical Framework for Complex Community-Based Interventions
- Choosing the right mix: lessons on culturally relevant treatment from the evaluation of the Drug and Alcohol Multicultural Education Centre’s Counselling Service
- Human resource governance: what does governance mean for the health workforce in low- and middle-income countries?
- Global social policy studies: Conceptual and analytical reflections
- Can community level interventions have an impact on equity and utilization of maternal health care? Evidence from rural Bangladesh
Category Specific RSS